CorMedix (CRMD) reported Q4 preliminary net revenue Thursday of $127 million.
Analysts surveyed by FactSet expected $128.3 million.
The company said it expects 2026 revenue of $300 million to $320 million.
Analysts surveyed by FactSet expect $435.7 million.
CorMedix also named Chief Executive Joseph Todisco chairman of the board of directors, succeeding Myron Kaplan, who will become lead independent director, which is a new position on the board.
Shares of CorMedix were down more than 8% pre-bell.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments